/Companies

PreDxion Bio

DefunctYC S17

San Francisco, US · Founded 2017 · 6 employees · 5 known investors

Find your way into PreDxion Bio

Sign up to see every warm intro you have to PreDxion Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the PreDxion Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

PreDxion Bio develops a rapid saliva-based antigen test for detecting SARS-CoV-2 S-protein in asymptomatic and presymptomatic patients, scalable using semiconductor fabrication processes. Its original technology, spun out of the University of Michigan, is a near real-time cytokine and biomarker detection platform for monitoring immune response in critically ill patients, including those undergoing CAR-T therapy.

BiotechDeep TechHealthtechMedical DevicesMicrofluidicsNanosensorsCOVID-19United States of AmericaAmerica / CanadaPartly Remote

Founders & leadership· Y Combinator alumni (S17)

PreDxion Bio was founded in 2017 by Walker McHugh and Timothy Cornell.

WMWalker McHugh
Walker McHughFounderHe holds an undergraduate degree in immunology and a graduate degree from the Medical Product Development Program at the University of Michigan College of Engineering.
TCTimothy Cornell
Timothy CornellFounder
CL
Caroline LandauCOO
SK
Steven KayeVice President, Engineering

Investors · 5

Related companies · 5

Companies working in the same space as PreDxion Bio.

Legal entities · 1

corporate structure
PreDxion Bio, Inc.

Frequently asked questions

What does PreDxion Bio do?
PreDxion Bio develops a rapid saliva-based antigen test for detecting SARS-CoV-2 S-protein in asymptomatic and presymptomatic patients, scalable using semiconductor fabrication processes. Its original technology, spun out of the University of Michigan, is a near real-time cytokine and biomarker detection platform for monitoring immune response in critically ill patients, including those undergoing CAR-T therapy.
Who founded PreDxion Bio?
PreDxion Bio was founded by Walker McHugh, Timothy Cornell in 2017.
Who are PreDxion Bio's investors?
PreDxion Bio's investors include Y Combinator, Agrolimen Ventures, Hillsven, Invest Detroit, SignalFire.
Where is PreDxion Bio headquartered?
PreDxion Bio is headquartered in San Francisco, US.